Dynavax’s Heplisav Heads To Advisory Panel, But Will It Drudge Up Old Safety Issues?

Company says its hepatitis B vaccine, which had been placed on clinical hold at one point during its Phase III trials, will be discussed at a FDA advisory committee in November.